MANTA Ultrasound Closure Study

Inclusion Criteria: * Candidate for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter valve replacement (TAVR) via a 10-20F device or sheath (12-25F OD) with common femoral artery approach * Vessel size would allow for access for the MANTA VCD based on vessel size as determined by baseline CTA: minimum vessel diameter of 5mm for the 14F MANTA VCD and 6mm for the 18F MANTA VCD * Understand and sign the study specific written informed consent form and PHI authorization * Able and willing to fulfill the follow-up requirements Exclusion Criteria: * Patients known to be pregnant or lactating * Patients who have a systemic infection or a local infection at or near the access site * Patients with significant anemia (hemoglobin ≤10 g/DL) * Patients who are morbidly obese or cachectic (BMI \>40 or \<20kg/m2) * Patients with a known bleeding disorder including thrombocytopenia (platelet count \<100,000 cells/UL), thrombasthenia, hemophilia, or von Willebrand disease * Patients with allergy to bovine materials or any other device material, including collagen and/or collagen products, polyglycolic or polylactic acid, stainless steel or nickel * Patients with a femoral artery puncture in target groin within the prior 30 days, prior vascular closure device placement in the target common femoral artery within 3 months, or any prior target femoral artery access-related complication * Patients who have undergone use of an intra-aortic balloon pump (IABP) through the arterial access site within 30 days prior to the baseline evaluation. * Patients who have a Common Femoral Artery (CFA) with visible calcium and/or tortuosity, as determined by baseline CTA, precluding safe access and likely to interact with large bore access site arteriotomy, determined by investigator. * Patients with previous iliofemoral intervention in region of access site, including but not limited to prior atherectomy, stenting, surgical or grafting procedures in the access area * Patients in whom oral anticoagulation therapy cannot be stopped for the peri procedural period or patients with INR \>1.8 at the time of the procedure * Patients who are unable to ambulate at least 6 meters without assistance at baseline * Patients with renal insufficiency (serum creatinine \>2.5 mg/dl) or on dialysis therapy * Patients with existing nerve damage in the ipsilateral leg * Patients with a further planned endovascular procedure within the next 30 days * Patients who have already participated in this IDE study * Patients who are currently participating in another clinical study of an unapproved investigational device or drug that has not concluded the follow-up period or patient currently participating in another clinical study likely to influence hemostasis and vascular complications * Patients who cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence, psychiatric condition or life threatening disease * Patients who have a common femoral artery \<5mm in diameter for the 14F MANTA VCD or \<6 mm in diameter for the 18F MANTA VCD, common femoral artery stenosis resulting in a vessel diameter \<5mm in diameter for the 14F MANTA VCD or \<6 mm in diameter for the 18F MANTA VCD, or \> 50% diameter femoral or iliac artery stenosis * Patients in whom, during initial access of the artery, arteriotomy and surrounding anatomy cannot be visualized and identified clearly under U/S imaging and/or if the vertical depth from the surface of the skin to target area of the common femoral artery measures greater than 6cm